1	Cross-Cultural Adaptation and Validation of the 5C Scale to Identify Factors Associated
2	With COVID-19 and Influenza Vaccine Hesitancy Among Healthcare Workers in Cape
3	Town, South Africa – A Protocol
4	
5	Short Title: Measuring Vaccine Hesitancy Among Healthcare Workers in Cape Town
6	
7	Samuel M Alobwede ^{a,b} , Patrick DMC Katoto ^{c,d} , Sara Cooper ^{c,e,f} , Evelyn N Lumngwena ^{g,h} ,
8	Elvis B Kidzeru ^{i,j,k} , Rene Goliath ¹ , Amanda Jackson ¹ , Charles S Wiysonge ^{c,e,f,m,*} , Muki S
9	Shey ^{a,l,n,*,#}
10	
11	Affiliations:
12	^a Department of Medicine, Faculty of Health Sciences and Groote Schuur Hospital, University
13	of Cape Town, Cape Town, South Africa
14	^b Department of Research and Innovation, Clinical division, Partners in Sexual Health, Cape
15	Town, South Africa.
16	^c Cochrane South Africa, South African Medical Research Council, Francie van Zijl Drive,
17	Parow Valley, Cape Town, South Africa
18	^d Centre for General Medicine and Global Health, Department of Medicine, University of Cape
19	Town, Cape Town, South Africa
20	^e Department of Global Health, Stellenbosch University, Cape Town, South Africa
21	^f School of Public Health and Family Medicine, University of Cape Town, Cape Town, South
22	Africa
23	^g School of Clinical Medicine, Faculty of Health Sciences, University of Witwatersrand,
24	Johannesburg, South Africa

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

25	^h Centre for the Study of Emerging and Re-emerging Infections (CREMER), Institute of
26	Medical Research and Medicinal Plant Studies (IMPM), Ministry of Scientific Research and
27	Innovation, Yaoundé, Cameroon
28	ⁱ Centre for Research on Health and Priority Pathologies (CRHPP), Institute of Medical
29	Research and Medicinal Plant Studies (IMPM), Ministry of Scientific Research and
30	Innovation, Yaoundé, Cameroon
31	^j Hair and Skin Research Laboratory, Division of Dermatology, Department of Medicine,
32	Faculty of Health Sciences and Groote Schuur Hospital, University of Cape Town, Cape Town,
33	South Africa
34	^k Division of Radiation Oncology, Department of Radiation Medicine, Faculty of Health
35	Science, University of Cape Town, and Groote Schuur Hospital, Cape Town, South Africa
36	¹ Wellcome Centre for Infectious Disease Research in Africa (CIDRI-Africa), Faculty of Health
37	Sciences, University of Cape Town, Cape Town, South Africa
38	^m HIV and other Infectious Diseases Research Unit, South African Medical Research Council,
39	Durban, South Africa
40	ⁿ Institute of Infectious Disease and Molecular Medicine (IDM), Faculty of Health Sciences,
41	University of Cape Town, Cape Town, South Africa
42	
43	*These authors contributed equally to this work.
44	
45	#Corresponding author: A/Professor Muki S Shey, Department of Medicine & Wellcome
46	Centre for Infectious Diseases Research in Africa (CIDRI-Africa), Institute of Infectious
47	Disease and Molecular Medicine (IDM), Faculty of Health Sciences, University of Cape Town,
48	Cape Town, South Africa. Email: muki.shey@uct.ac.za; Tel: +27 21 650 1731

49

50

51

52 Abstract

53 Background: Healthcare workers are at an increased risk of acquiring vaccine-preventable 54 diseases and are known to be reliable source of information for the patients and their relatives. 55 Knowledge and attitudes of Healthcare workers about vaccines are thus important determinants 56 of their own vaccination uptake and their intention to recommend vaccinations to their patients. 57 However, culturally adapted tools and studies to address vaccine uptake and hesitancy as well 58 as related behaviours among Healthcare workers in the Global South are limited.

59 Methods: We propose a mixed methods project to understand the extent and determinants of 60 vaccination hesitancy among Healthcare workers and construct a validated scale to measure 61 this complex and context-specific phenomenon in Cape Town. We will summarise responses 62 as counts and percentages for categorical variables and means with standard deviations (or 63 median with inter quartile ranges) for continuous variables. We will run the Shapiro-Wilks test 64 to assess the normality. Analysis of the variance, chi-square tests, and equivalents will be conducted as appropriate for group comparisons. Logistic regression models will also be 65 66 performed to assess association between variables.

We will focus on the seasonal influenza and COVID-19 vaccine. We will use an existing tool developed and validated in Germany and the United States of America to measure five psychological determinants of vaccination (referred to as the 5C scale), as the basis to develop and validate a scale to measure the scope and determinants of vaccine hesitancy and acceptance among Healthcare workers in Cape Town.

Discussion and conclusion: Through this study, we hope to expand the scientific evidence
based on vaccination acceptance and demand among Healthcare workers in South Africa and

- 74 build resources to enable better understanding of, detection, and response to vaccination
- 75 hesitancy in Cape Town.
- 76
- 77 Keywords: COVID-19 vaccines, Influenza vaccines, vaccine attitudes, vaccine confidence,
- vaccine hesitancy, healthcare workers, Cape Town.

80 Background

81 The World Health Organization (WHO) identified vaccine hesitancy (also referred to as vaccination hesitancy) as one of the top ten threats to global health in 2019 (1, 2, 3). Vaccination 82 83 hesitancy refers to the delay in acceptance or refusal of vaccines, despite availability of 84 vaccination services. Vaccination hesitancy is complex and context-specific, varying across 85 time, place, and vaccines (4). We use the terms vaccine hesitancy and vaccination hesitancy 86 interchangeably in this proposal, to refer to the same phenomenon. The National Advisory 87 Group on Immunization (NAGI) in South Africa has identified both vaccination of healthcare 88 workers (HCWs) and vaccination hesitancy as important issues that need urgent action. In line 89 with this plight, NAGI has formed working groups to find lasting solutions to these issues. There 90 is thus an urgent need for local data on vaccine hesitancy and uptake among HCWs in Cape 91 Town and South Africa as a whole.

Prior to COVID-19 pandemic, work related to vaccine hesitancy among HCWs evaluated
vaccines most requested by healthcare establishments for staff members, which include
influenza vaccines and hepatitis B.

95 HCWs were more likely to recommend vaccination if they were themselves vaccinated. A 96 study in the United Kingdom (UK) showed that nurses who were vaccinated were more likely 97 to recommend vaccination to their peers and other patients (17). A Nigerian study similarly 98 reported that female nurses were more likely to recommend HPV vaccination when they 99 expressed a willingness to be vaccinated themselves (18). Further research in Israel found that 100 physicians were more likely to recommend vaccinations to patients if they accepted the 101 influenza vaccine for themselves (19). Moreover, Canadian study also found that midwives who reported being immunized themselves were more likely to have trust in the safety and 102 103 efficacy of influenza vaccine, and subsequently recommended vaccination to their colleagues

104 and patients (20). It was also found tin a US study that recommending the influenza vaccine to 105 co-workers, patients, or patients' families, was also associated with HCWs themselves being 106 vaccinated (21). HCWs in Iran who intended to be vaccinated against influenza in the next 107 season were also 4.6 times more likely to recommend vaccination to their patients than those 108 who did not intend to be vaccinated (22). However, little is known about the drivers of 109 vaccination hesitancy among HCWs in Cape Town, and the extent of its impact on vaccination 110 coverage; as most research on vaccination hesitancy have been conducted in high-income 111 countries (HICs) (9, 10). In addition, tools to measure determinants of vaccination hesitancy 112 and uptake are scarce and none of the current existing ones have been validated in South Africa. 113 Furthermore, there are no studies on Influenza vaccine hesitancy among HCWs in Cape Town 114 and South Africa in general. A measurement tool for vaccination hesitancy developed in 115 Germany (known as the 5C scale, Appendix 1) has been shown to be valid and easy to 116 administer in Europe and North America (5). The 5C scale contains a series of items (or 117 questions) to assess five determinants of vaccine hesitancy: confidence, complacency, 118 constraints (convenience), rational calculation, and collective responsibility (5). However, as 119 with other vaccination hesitancy measurement tools (6, 7, 8) this scale is based on research 120 conducted in high-income countries and has not been validated in South Africa. This 121 potentially limits its generalizability to healthcare worker vaccination in Cape Town; hence 122 there is need to adapt, pilot and validate this tool in our setting to determine factors associated 123 with both Influenza and COVID-19 vaccines hesitancy among HCWs in the Western Cape, 124 South Africa. This study aims to fill these gaps through developing capacity for vaccination hesitancy research in Cape Town and a validated measurement tool for vaccination hesitancy 125 126 in this setting. The validated tool would be useful to better understand the burden and causes of vaccination hesitancy among HCWs in South Africa, monitor changes and trends over time 127 128 and place in the country, and enhance the comparability of research results across the country.

129

130 Materials and methods

131 Aims, design, population, and study setting

132 The methodological framework for this study is adapted from Betsch and colleagues (5) and 133 the WHO Guide to Tailoring Immunization Program (TIP) (55). Betsch and colleagues found 134 in studies conducted in Germany and the USA that the determinants of vaccine hesitancy vary depending on the vaccine, the target group, and the country of study (5). We will focus this 135 136 project on HCWs and on two vaccines, the seasonal influenza vaccine, and the COVID-19 137 vaccine. In this cross-sectional study, we aim to understand the extent and determinants of 138 vaccination hesitancy among HCWs in Cape Town and to construct a validated tool to measure 139 the phenomenon of vaccination hesitancy in this population. We will focus on two vaccines: 140 an existing vaccine recommended for HCWs (the seasonal influenza vaccine) and the vaccine 141 for COVID-19 for which HCWs are a priority target population. Cape Town has close to 32.479 142 health care workers according to (Western Cape annual report 2020/2021). By august 2021, 143 the Western Cape Government had administered a cumulative total of 1 426 278 COVID-19 144 vaccines to healthcare workers, The study will take place within the Cape Metro of the Western Cape of South Africa. All healthcare facilities in the Cape Metro (whether providing integrated 145 146 primary healthcare, level 2, or level 3 services) will be approached for participation in the 147 study, making all healthcare facilities in the Cape Metro eligible for inclusion in the study and 148 thus will avoid selection bias in the recruitment of participants. The City of Cape Town is home 149 to about 4.4 million people, making it the second metro by population size in South Africa and 150 the Metro also prides itself as the tourism hub of the country. Cape Town has a coastline of 151 294km and is also bounded by the Atlantic Ocean to the south and west. The city positions 152 itself in Table Bay, bottom end of the African continent. It is the second largest city in South 153 Africa and the capital of Western Province.

154 Globally, as of 22 May 2022 according to the WHO COVID-19 dashboard [66], there have 155 been 524 339 768 confirmed cases of SARS-CoV-2 infections, the virus that causes COVID-156 19, including 6 281 260 deaths from COVID-19. A total of 11 752 954 673 vaccine doses have 157 been administered globally by 22 May 2022. In South Africa by 22 May 2022, there have been 3 915 253 confirmed cases of SARS-CoV-2 infections with 100 898 deaths from COVID-158 159 19 reported to WHO. As of 22 May 022, a total of 35 744 528 vaccine doses have been administered in South Africa. In the Western Cape Province, a total of 701 607 confirmed cases 160 161 of SARS-CoV-2 infections were reported with 22 065 deaths from COVID-19.

162 The 5C scale tool

The five psychological antecedents of vaccination in the 5C scale are confidence, complacency, 163 164 constraints or convenience, rational calculation, and collective responsibility (5). Confidence 165 refers to the trust in (i) the effectiveness and safety of vaccines, (ii) the system that delivers 166 them, including the reliability and competence of the health services and health professionals, 167 and (iii) the motivations of policy-makers who decide on the need of vaccines (5). The authors 168 of the 5C scale found in Europe and North America that individuals who lack confidence hold 169 negative attitudes towards vaccinations, do not believe that vaccines are safe and effective, and 170 do not trust the system that provides vaccination (5). Complacency occurs when "perceived risks of vaccine-preventable diseases are low and vaccination is not deemed a necessary 171 172 preventive action"(5). Individuals scoring high in complacency do not perceive any risks from 173 vaccine-preventable diseases. Constraints refer to practical barriers such as costs and lack of 174 time or access. Rational calculation of risks and benefits of vaccination involves extensive searching for information about vaccination. *Collective responsibility* describes the situation 175 176 whereby people understand the value of, and engage in vaccination, to contribute to herd immunity (5). 177


178

179 **Phases of the study**

180

181 Our study will be conducted across four phases as described below

182



184

185 Phase 1: Adaptation of the Original 5C scale to the 5C+ Cape Town Scale

In this phase 1, we aim to gain deeper understanding of vaccine hesitancy among HCWs in 186 Cape Town by engaging with relevant stakeholders. Through such engagement the study team 187 188 will review the existing items in the 5C scale (6, 7, 8). This will further inform the identification 189 and generation of additional factors and corresponding items in Cape Town, South Africa (5C+ Cape Town Scale). The expanded 5C+ Cape Town Scale will be translated into English, 190 191 isiXhosa, and Afrikaans (Phase 1a). Based on our experience in the region, the added items 192 will include willingness to be vaccinated and the compatibility of vaccination with religious 193 beliefs. We will send the adapted 5C scale (the 5C+ Cape Town Scale) to at least five vaccine 194 experts and HCWs in South Africa, to get feedback on whether the items are easy to understand. This engagement will help to ensure the face validity and comprehensibility of the items of the 195 196 5C+ Cape Town Scale (56). HCWs will then complete a questionnaire on their attitudes to

197 COVID-19 and influenza vaccines, including willingness to get vaccinated (Phase 1b). The 198 survey will be conducted both face-to-face and web-based in accordance with the COVID-19 199 regulation in place.

200 Phase 2: Validation of the 5C+ Cape Town Scale

201 The objective of this phase is to assess the reliability, construct, concurrent, and predictive 202 validity of the adapted 5C scale for HCWs (the 5C+ Cape Town scale), and to develop a short 203 scale (61) (Phase 2a). The validation procedure is necessary to ensure that the items assessing 204 one of the original 5C factors produce similar results after adaptation in phase 1a and 1b as 205 compared to the original version. Based on the findings, we may further refine the 5C items for 206 the Cape Town specific scale (5C+ Cape Town) for further testing (Phase 2b). Construct 207 validity queries whether the tool assesses what it aims to assess. Convergent validity will refer 208 to the extent to which a measure correlates with other indicators of the same construct. 209 Discriminant validity will refer to the extent to which a measure does not correlate with 210 indicators of other constructs that are theoretically or empirically distinct. Concurrent validity 211 will involve relating a measure to criteria assessed at the same time as the measure itself. 212 Predictive validity will encompass associations with criteria that are assessed at some point in 213 the future (5).

214 Phase 3: Stakeholders' engagement

The objective of Phase 3 will be to share, discuss and obtain feedback on the findings from phases 1 and 2, including how the findings can be promoted for use within policy, practice, and research. We will identify and generate a list of key groups and individuals involved in the design, planning and implementation of healthcare worker vaccination (17). This will include policymakers, program and facility managers, professional associations, oversight, and advisory bodies, HCW unions, and HCWs themselves. The list will be developed iteratively by the research team, drawing on their collective knowledge of the relevant stakeholders,

scoping of the literature, and team discussions. The methodology for developing the stakeholder list will be guided by the methods developed in a previous study to identify a complex multiple stakeholder reference sample (20)

Engagement workshops will then be conducted with a selection of individuals from identified stakeholder groups. We will employ a maximum variation purposive sampling approach (21) to ensure that workshop participant groups comprise 'information-rich' cases (i.e. individuals who are especially knowledgeable about or experienced in HCW vaccination) and reflect wide ranging socio-demographic characteristics and stakeholder groups.

The stakeholder engagement workshops will be conducted face-to-face or online, depending on existing Covid-19 guidelines. Each workshop will include approximately 10-15 participants. The number of workshops conducted will be determined iteratively, depending on the response rate amongst stakeholders and the findings that emerge.

234 The workshop will begin with a presentation of the findings from phases 1 and 2. Thereafter 235 participants will be encouraged to provide feedback, including their views about: the extent 236 and determinants of vaccination hesitancy among HCWs identified by the study, whether these 237 findings resonate (or not) with their own experiences, potential issues not identified by the 238 study, the 5C+ Cape Town Scale (including its acceptability and usability in their local 239 settings), as well as the potential implications of the study findings. The discussions will also 240 obtain participants views and experiences regarding how the findings can be promoted for use 241 within policy, practice, and research to strengthen the immunisation program among HCWs.

We will use multiple participatory methods to gather participant input and facilitate two-way engagement between the researchers and stakeholders (22) Potential techniques to be used include, brainstorming, meta-planning, listing, mind mapping, and ranking exercises and will comprise both large group discussions and small break-out group work. We will carefully preplan the composition of the small groups, considering the power-dynamics between

stakeholder groups and how the views of more marginalised individuals can be properlyexpressed.

249 With the permission of participants, all workshops will be audio-recorded and transcribed 250 verbatim, and all personal identifying information will be removed from transcripts. The 251 anonymised transcripts will be downloaded into NVivo, a software programme that aids with 252 the management and analysis of qualitative data. The data will be analysed through a thematic 253 analysis, using the phases described by Braun and Clarke (23). The analysis will identify key 254 themes regarding stakeholders' views about the findings and strategies to enhance their uptake, 255 as well as their views about the 5C+ Cape Town Scale and its usability. One researcher will 256 lead the analysis, with regular discussion and feedback from other researchers.

257 Healthcare workers recruitment and sample size estimation

All HCWs working in Cape Town will be eligible for inclusion. This will include nurses, medical doctors, pharmacists, hospital administrative personals, health researchers etc. Permission has been received from all the relevant authorities (including the University of Cape Town Human Research Ethics Committee, the Western Cape Provincial Department of Health. We will contact facility managers who will assist in identifying potential participants. The purpose of the study will be explained to both the managers and the potential participants.

The total sample size for the validation survey will be at least 300 HCWs, based on best practice 264 265 recommendations for scale validation and performance of exploratory factor analyses (63). 266 Given that the assessment of validity is based on the inspection of correlation patterns, studies 267 suggest using a sample comprising at least 300 participants, which will allow detecting small 268 correlations (r=0.2) with at least 95% power (62). While we will aim to recruit a sample size 269 that is diverse and representative of HCWs in Cape Town, we are also mindful of the fact that representative sampling is a very complex endeavour and highly context-specific among 270 271 HCWs during the pandemic period (64, 65).

272 Data collection and data Management

This study will have no direct impact on clinic and hospital healthcare operations. The studywill be performed with minimal direct contact with staff at healthcare facilities.

Healthcare workers will complete the consent form and questionnaire either as a hardcopy (provided to healthcare facilities) or through an online platform whereby the data will be directly captured onto the Research Electronic Data Capture (REDCap) database. The duration for completion of the consent form and questionnaire will be about 20 minutes which can be done at the convenience of the HCW. The 5C questionnaire designed to capture 23 exploratory variables including socio-demographic characteristics and attitudes of HCWs towards COVID-19 and influenza vaccination has been designed (Appendix 2).

282 Expected outcome

283 The primary outcome of this study is a validated tool to measure vaccination hesitancy and 284 acceptance among HCWs in Cape Town, with focus on COVID-19 and influenza vaccines. 285 The adapted and validated long and short scales have the potential to be applicable to other 286 parts of South Africa, to other target groups in the country, and to vaccination programs in 287 general. This would be an important contribution to science, as no tool to measure the 288 determinants of vaccination hesitancy and acceptance among HCWs has been previously tested 289 in an African country. The secondary outcome will involve assessing the proportion and related 290 risk factors of COVID-19 and influenza vaccines hesitancy and acceptance among HCWs. 291 Lastly, the tertiary outcome will evaluate the process, barriers, and enablers of implementing 292 the 5C+ Cape-Town scale in South Africa and other similar health settings in the global south. 293 Statistical analyses

In the analyses, we will first assess the reliability of the 5C+ Cape Town scale (by assessing Cronbac's alpha) and then determine its validity, i.e., find out whether it measures what it

intends to measure. For this, we will investigate whether the 5C+ factors are associated with
theoretically similar constructs (e.g. confidence should correlate with attitude) (5). To do so,
we will calculate Pearson's correlations between each 5C+ factor and the validation constructs.
The pattern of results will inform the item selection process – both reliability and validity will
be optimized in this process.

301 Then we will assess which Cape Town 5C+ factors are associated with vaccination behaviour 302 or intention, and how strong these relations are. For vaccination behaviour we will find out for 303 each participant if he/she has previously been vaccinated against seasonal influenza and if 304 he/she intends to take the COVID-19 vaccine and influenza vaccine during the next influenza 305 season. For the survey, we will categorise participants as willing or unwilling to vaccinate when 306 a vaccine will be available to them. For descriptive analysis, we will summarise responses as 307 counts and percentages for categorical variables and means with their standard deviations (or 308 medians and respective inter quartile ranges) as appropriate for continuous variables. We will 309 run the Shapiro-wilks test to assess the normality. Analysis of the variance (ANOVA), chi-310 square tests, and equivalents will be conducted as appropriate for group comparisons. Logistic 311 regression models will also be performed to assess the association between each item of the 5C 312 instrument and COVID-19 and influenza vaccines hesitancy and acceptance.

313 Finally, we will develop a short scale by selecting one item per subscale that best represents 314 each subscale. The one item that correlates with the validation construct in the same direction 315 and to a similar extent as the whole scale will be selected. As a result of this process, we will 316 have a validated long and short scale for measuring vaccine hesitancy and acceptance among 317 HCWs in Cape Town, each having several subscales that capture the psychological 318 determinants of vaccination in a culturally appropriate and adapted way. Spearman's rank 319 correlation coefficient will be used to calculate concurrent validity between the 5C original 320 scale and the 5C+ Cape Town long and short scales. A two-sample t-test will be used to

compare the 5C+ Cape Town group scales/scores to the original. For nonparametric data,
Spearman's rho, Inter-Class Correlation Coefficient (ICC), and Wilcoxon paired test will be
used for reliability assessment. Cronbach's alpha will be used to determine internal consistency
for the total score. We will consider a p-value < 0.05 to indicate statistically significant results.
All analyses will be performed in R Foundation for Statistical Computing, Vienna, Austria))
V4.0.5 software.

327 Ethical declaration

Ethical approval for this study was obtained from the University of Cape Town Human Research Ethics Committee (HREC Ref# (858/2020.). Furthermore, administrative permission has been obtained from the Western Cape Provincial Department of Health (WC, (# WC_202101_014), and the management of the various hospital where data will be collected.

332 The study objectives will be clearly explained in an information sheet, before the consent form 333 (Appendix 3) is signed and each participant will be made to know that they can discontinue 334 their participation at any time. Data will be used only from participants who signed the consent 335 form before participation. Confidentiality will be maintained by collecting only participant 336 demographics without names and other participant information protected. Further to that, only 337 age ranges will be used for further data processing with no information that my lead to identification of any participant. The risks associated with this study are minimal for 338 339 participants.

340

341 Discussion and conclusion

Our study builds on the 5C scale described previously (5). The 5C is suitable for this study
because it captures multiple dimensions of vaccine hesitancy; extending the scope of existing
vaccine hesitancy measuring scales that focus primarily on confidence-related aspects. Another

advantage of the 5C scale is that it assesses five determinants of vaccination with only 15 questions, and a shorter version of only five questions (5). Adapting and piloting this instrument in our setting will then allow us to understand whether the 5C scale is applicable to HCWs in South Africa. This question matters because studies in Western countries have shown that the determinants of vaccine hesitancy vary depending on the target group, the country of study, and the vaccine (5) and that vaccine hesitancy among HCWs might reduce effort to curb the ongoing pandemic.

352

353 Vaccine decision making process and HCWs

354 Vaccination is often cited as one of the most effective ways of controlling infectious diseases 355 (11). However, while most people vaccinate according to the recommended schedule, this 356 success is being challenged by individuals and groups who choose to delay or refuse vaccines 357 (12). HCWs have had different responses to this changing environment. Certain health facilities 358 have dropped patients if they refuse vaccination (13, 12), making the case that it puts their other 359 patients at risk, while in other hospitals or clinics, some HCWs decided to delay vaccination or 360 administer partial doses, in order to protect the trust relationship with their patient, although 361 recognizing there is no clinical evidence to support such an approach (14). The vaccination decision-making process includes people who agree to be vaccinated, because they see it as the 362 363 norm, and those that take their time weighing up the pros and cons of vaccination, talking with 364 family, friends, or members of their community, searching the internet, and asking their HCWs 365 for advice. The relevance of HCWs vaccine hesitancy is a process that has been well 366 documented (15). HCWs are one of the strongest influences in vaccination decisions and it is 367 on this basis that this study is grounded. Despite variations in reasons for hesitancy across 368 geographies and vaccines among HCWs hesitancy, there are common themes that emerge 369 globally (12, 16).

370 The WHO Strategic Advisory Group of Experts on Immunization (SAGE) convened a working 371 group to investigate the nature and scope of vaccine hesitancy, which has created a model of 372 determinants of vaccine hesitancy organized around three domains, namely: (1) contextual 373 influences, (2) individual or social group influences, and (3) vaccine and vaccination-specific issues (12). All three domains include the influence of others on vaccine hesitancy. Domain 1 374 375 (contextual influences) includes influential leaders and individuals; domain 2 (individual or 376 social group influences) includes personal experience with and trust in the health system and 377 provider; and domain 3 (vaccine and vaccination-specific issues) includes the role of HCWs which is the focus of this study. In a study about HPV vaccination in Cameroon, the most 378 379 important factors considered among nurses when deciding to recommend the vaccine included 380 understanding the effectiveness and safety of the vaccine (27). In another example, a study on 381 HCWs vaccine hesitancy in the USA found that those who were not confident in the vaccine's 382 efficacy and protective value were less likely to recommend it to patients or accept it 383 themselves (21). Irrespective of the influence of HCWs vaccination behaviour on peers and 384 others, the attitudes of HCWs towards vaccination may have a powerful influence. For 385 example, a study about doctors' attitudes towards measles, mumps and rubella (MMR) 386 vaccination in Denmark illustrated that the average vaccination rate in practices with 387 unreservedly positive attitudes about vaccination was 85%, compared with 69% in practices 388 with more guarded attitudes (23).

389 Strengths and limitations of the study

390 Study strengths

With a broad range of scenarios, it is expected that the research will generate evidence that is potentially applicable to other parts of South Africa. This study will produce relevant knowledge and has the potential for effecting policy changes (56). A complex web of influences and interactions affect the degree to which evidence is used by policymakers and 395 managers. Among the many critical factors, the involvement of, and buy-in from, policymakers 396 and managers at an early stage in the research is an essential element for ensuring that emerging 397 evidence can be disseminated in timely and appropriate formats. This is the reason why we 398 have already started engagement with the management of the healthcare facilities in Cape 399 Town Metro.

400 Vaccine hesitancy is complex and context-specific, varying across time, place, and vaccines.
401 It may be related to a specific product such as a new vaccine, new vaccine formulation, or new
402 route of administration of a vaccine. Most of the research on the topic comes from HICs and
403 not much is known about this issue in low and middle-income countries generally and South
404 Africa specifically.

This study also draws on the WHO Guide to Tailoring Immunization Program (TIP) (55). The TIP framework takes a broader approach to other measurement tools and helps to 1) identify and prioritize vaccine hesitant populations and subgroups, 2) diagnose and distinguish the demand and supply–side barriers to vaccination in these populations, and 3) design evidenceinformed responses to vaccine hesitancy appropriate to the setting, context, and hesitant population. This framework will help us to understand HCW vaccine hesitancy and better distinguish it from the broader range of barriers and facilitators facing HCWs vaccination.

412 Study limitations

The study limitations include that if participants lack understanding of certain questions, they will not complete the entire questionnaire for those that will complete the questionnaire online. This may lead to some exclusions for incomplete data. The second limitation is that the study will be cross-sectional assessing vaccine hesitancy at a single time point. There is possibility that attitudes of HCWs about vaccine can change over time.

418 **Data availability and dissemination plans**

419 **Dissemination plans**

The results of this study will be published in scientific journals to allow researchers from sub-Saharan Africa and other countries that have not yet tested the 5C model to be able to study vaccine hesitancy in their respective settings. Moreover, the outcomes of these study will inform HCWs information sessions within our hospitals and teaching hospitals and may further inform re-enforcement of lectures on immunisation and vaccines. The outcomes will further be summarised to inform policy makers on how to better improve campaigns for COVID-19 and influenza vaccination among HCWs.

427 Data availability Statement

428 Main research design and tool will be made freely available to the broader academic 429 community and public. Focus will be placed on data management and protection of participants 430 information as well as faithful and reproducible record keeping, with an emphasis on 431 transparency and accountability in methods utilised. Primary outcome being identification of 432 factors associated with vaccine hesitancy and affecting vaccine uptake by healthcare workers. 433 The results will be documented in text, plots, and images. Findings will be legible, reasonably 434 organized, and sufficiently detailed for future use by other researchers wishing to reproduce 435 the outcome. Research Electronic Data Capture (REDCap) computer software will be used to 436 capture, store and generate data. All raw data in electronic format will be stored in an organised fashion and widely used and accessible formats will be employed. All stored electronic data, 437 438 updated frequently, will be continuously backed up to external (including cloud-based) media. 439 Detail results of the main research products will appear online in digital format in text, tables, 440 plots, and images in peer-reviewed journal articles and/or conference proceedings. Records 441 will be durable, accessible, and made safe from tampering or falsification.

442 **Conclusion**

In this survey of vaccine hesitancy among HCWs, we will adapt, pilot, and validate the 5C
scale instrument among HCWs in South Africa. By doing so, we will gain knowledge on the

445 extent and determinants of vaccination hesitancy among HCWs in an African context. This 446 may facilitate other researchers to study this complex and context-specific phenomenon of vaccination hesitancy in South Africa and generally in Africa. This would expand the evidence 447 448 base on vaccination hesitancy in Africa and enhance the generalizability of current theoretical causal models of vaccination hesitancy. Such knowledge will enable us and other researchers 449 450 in the future to design interventions to reduce vaccination hesitancy, which are evidence-based, contextually appropriate, and focused on causal mechanisms, thus improving their 451 452 effectiveness, cost-efficiency, and acceptability.

453

454 Abbreviations

- 455 5C Scale: Tool to measure five determinants of vaccine hesitancy (confidence, complacency,
- 456 constraints, rational calculation, and collective responsibility)
- 457 5C+ Scale: 5C scale adapted to Cape Town
- 458 CHC: Community Health Center
- 459 GVAP: Global Vaccine Action Plan
- 460 HCW: Healthcare Workers
- 461 HICs: High Income Countries
- 462 HREC: Human Research Ethics Committee
- 463 MMR: Measles, Mumps and Rubella
- 464 NAGI: National Advisory Group on Immunization
- 465 SAGE: Strategic Advisory Group of Experts on Immunization
- 466 SWOT: Strengths Weaknesses, Opportunities, and Threats
- 467 TIP: Tailoring Immunization Program
- 468 UK: United Kingdom
- 469 UCT: University of Cape Town

- 470 USA: United States of America
- 471 WP: Western Cape province
- 472 WHO: World Health Organization?

473 **References**

474	1.	World Health Organization. Ten threats to global health in 2019.					
475		https://www.who.int/emergencies/ten-threats-to-global-health-in-2019 [Internet].					
476		World Health Organisation (WHO). 2019. p. 1–18. Available from:					
477		https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-					
478		2019%0Ahttps://www.who.int/news-room/feature-stories/ten-threats-to-global-health-					
479		in-2019%0					
480	2.	Machingaidze S, Wiysonge CS, Hussey GD. Strengthening the Expanded Programme					
481		on Immunization in Africa: Looking beyond 2015. PLoS Med. 2013 Mar;10(3).					
482	3.	Larson HJ. The state of vaccine confidence. Vol. 392, The Lancet. 2018. p. 2244-6.					
483	4.	MacDonald NE, Eskola J, Liang X, Chaudhuri M, Dube E, Gellin B, et al. Vaccine					
484		hesitancy: Definition, scope and determinants. Vaccine. 2015 Aug;33(34):4161-4.					
485	5.	Betsch C, Schmid P, Heinemeier D, Korn L, Holtmann C, Böhm R. Beyond confidence:					
486		Development of a measure assessing the 5C psychological antecedents of vaccination.					
487		PLoS One. 2018;13(12):1–32.					
488	6.	Larson HJ, Jarrett C, Schulz WS, Chaudhuri M, Zhou Y, Dube E, et al. Measuring					
489		vaccine hesitancy: The development of a survey tool. Vaccine. 2015 Aug;33(34):4165-					
490		75.					
491	7.	Shapiro GK, Tatar O, Dube E, Amsel R, Knauper B, Naz A, et al. The vaccine hesitancy					
492		scale: Psychometric properties and validation. Vaccine. 2018 Jan;36(5):660-7.					
493	8.	Opel DJ, Taylor JA, Mangione-Smith R, Solomon C, Zhao C, Catz S, et al. Validity and					
494		reliability of a survey to identify vaccine-hesitant parents. Vaccine. 2011					
495		Sep;29(38):6598–605.					
496	9.	Cooper S, Okeibunor JC, Wiyeh A, Wiysonge CS. Knowledge advances and gaps on					

1

the demand side of vaccination. Vol. 19, The Lancet Infectious Diseases. Lancet
Publishing Group; 2019. p. 13–5.

- Cooper S, Betsch C, Sambala EZ, Mchiza N, Wiysonge CS. Vaccine hesitancy–a
 potential threat to the achievements of vaccination programmes in Africa. Vol. 14,
 Human Vaccines and Immunotherapeutics. Taylor and Francis Inc.; 2018. p. 2355–7.
- 502 11. Maduka O, Akpan G, Maleghemi S. Using Android and Open Data Kit Technology in
 503 Data Management for Research in Resource-Limited Settings in the Niger Delta Region
 504 of Nigeria: Cross-Sectional Household Survey. JMIR mHealth uHealth. 2017
 505 Nov;5(11):e171.
- Larson HJ, Jarrett C, Eckersberger E, Smith DMD, Paterson P. Understanding vaccine
 hesitancy around vaccines and vaccination from a global perspective: A systematic
 review of published literature, 2007-2012. Vol. 32, Vaccine. Elsevier BV; 2014. p.
 2150–9.
- 510 13. Mejia B. Doctors turning away unvaccinated children Los Angeles Times. 2015.
- 511 14. Kempe A, O'Leary ST, Kennedy A, Crane LA, Allison MA, Beaty BL, et al. Physician
 512 response to parental requests to spread out the recommended vaccine schedule.
 513 Pediatrics. 2015 Apr;135(4):666–77.
- 514 15. Wiley KE, Massey PD, Cooper SC, Wood N, Quinn HE, Leask J. Pregnant women's
 515 intention to take up a post-partum pertussis vaccine, and their willingness to take up the
 516 vaccine while pregnant: A cross sectional survey. Vaccine. 2013 Aug;31(37):3972–8.
- 517 16. Bouder F, Way D, Löfstedt R, Evensen D. Transparency in Europe: A Quantitative
 518 Study. Risk Anal. 2015 Jul;35(7):1210–29.
- Larson HJ, Smith DMD, Paterson P, Cumming M, Eckersberger E, Freifeld CC, et al.
 Measuring vaccine confidence: Analysis of data obtained by a media surveillance
 system used to analyse public concerns about vaccines. Lancet Infect Dis. 2013

- 522 Jul;13(7):606–13.
- 523 18. Zhang J, While AE, Norman IJ. Nurses' knowledge and risk perception towards seasonal
 524 influenza and vaccination and their vaccination behaviours: A cross-sectional survey.
- 525 Int J Nurs Stud. 2011 Oct;48(10):1281–9.
- 526 19. Makwe CC, Anorlu RI. Knowledge of and attitude toward human papillomavirus
 527 infection and vaccines among female nurses at a tertiary hospital in Nigeria. Int J
 528 Womens Health. 2011;3(1):313–7.
- Livni G, Chodik G, Yaari A, Tirosh N, Ashkenazi S. Attitudes, knowledge and factors
 related to acceptance of influenza vaccine by pediatric healthcare workers. J Pediatr
 Infect Dis. 2008 Jan;3(2):111–7.
- Lee T, Saskin R, McArthur M, McGeer A. Beliefs and practices of Ontario midwives
 about influenza immunization. Vaccine. 2005 Feb;23(13):1574–8.
- LaVela SL, Smith B, Weaver FM, Legro MW, Goldstein B, Nichol K. Attitudes and
 Practices Regarding Influenza Vaccination Among Healthcare Workers Providing
 Services to Individuals With Spinal Cord Injuries and Disorders. Infect Control Hosp
 Epidemiol. 2004 Nov;25(11):933–40.
- Askarian M, Khazaeipour Z, McLaws ML. Facilitators for influenza vaccination uptake
 in nurses at the Shiraz University of Medical Sciences. Public Health. 2011
 Aug;125(8):512–7.
- 541 24. Trier H. Doctors' attitudes and MMR-vaccination. Scand J Prim Health Care.
 542 1991;9(1):29–33.
- 543 25. Baron-Epel O, Bord S, Madjar B, Habib S, Rishpon S. What lies behind the low rates of
 544 vaccinations among nurses who treat infants? Vaccine. 2012 May;30(21):3151–4.
- 545 26. Marcu A, Rubinstein H, Michie S, Yardley L. Accounting for personal and professional
- 546 choices for pandemic influenza vaccination amongst English healthcare workers.

3

547 Vaccine. 2015;33(19):2267–72.

- Zhang J, While AE, Norman IJ. Nurses' vaccination against pandemic H1N1 influenza
 and their knowledge and other factors. Vaccine. 2012 Jul;30(32):4813–9.
- 550 28. Wamai RG, Ayissi CA, Oduwo GO, Perlman S, Welty E, Welty T, et al. Awareness,
- knowledge and beliefs about HPV, cervical cancer and HPV vaccines among nurses in
- 552 Cameroon: An exploratory study. Int J Nurs Stud. 2013 Oct;50(10):1399–406.
- Duval B, Gilca V, Boulianne N, Pielak K, Halperin B, Simpson MA, et al. Cervical
 cancer prevention by vaccination: nurses' knowledge, attitudes and intentions. J Adv
 Nurs. 2009 Mar;65(3):499–508.
- Brabin L, Stretch R, Roberts SA, Elton P, Baxter D, McCann R. The school nurse, the
 school and HPV vaccination: A qualitative study of factors affecting HPV vaccine
 uptake. Vaccine. 2011 Apr;29(17):3192–6.
- Gilca V, Boulianne N, Dubé E, Sauvageau C, Ouakki M. Attitudes of nurses toward
 current and proposed vaccines for public programs: A questionnaire survey. Int J Nurs
 Stud. 2009 Sep;46(9):1219–35.
- 32. Hoque ME, Monokoane S, Van Hal G. Knowledge of and attitude towards human
 papillomavirus infection and vaccines among nurses at a tertiary hospital in South
 Africa. J Obstet Gynaecol (Lahore). 2014 Feb;34(2):182–6.
- Ishola DA, Permalloo N, Cordery RJ, Anderson SR. Midwives' influenza vaccine
 uptake and their views on vaccination of pregnant women. J Public Heal (United
 Kingdom). 2013 Dec;35(4):570–7.
- Austvoll-Dahlgren A, Helseth S. Public health nurses' barriers and facilitators to the use
 of research in consultations about childhood vaccinations. Scand J Caring Sci. 2012
 Jun;26(2):271–8.
- 571 35. Ravlija J, Ivankovic A. Importance of health workers' communication in immunisation

- 572 programmes. HealthMED. 2012;6(2):672–7.
- 573 36. Hollmeyer H, Hayden F, Mounts A, Buchholz U. Review: Interventions to increase
 574 influenza vaccination among healthcare workers in hospitals. Influenza Other Respi
 575 Viruses. 2013 Jul;7(4):604–21.
- Wicker S, Doerr HW, Gottschalk R, Rabenau HF, Allwinn R. Influenza: Akzeptanz der
 schutzimpfung bei medizinischem personal Auswertung zur influenzasaison
 2006/2007. Dtsch Medizinische Wochenschrift. 2007;132(33):1683–7.
- 579 38. Launay O, Le Strat Y, Tosini W, Kara L, Quelet S, Lévy S, et al. Impact of free on-site
 580 vaccine and/or healthcare workers training on hepatitis B vaccination acceptability in
 581 high-risk subjects: A pre-post cluster randomized study. Clin Microbiol Infect. 2014
 582 Oct;20(10):1033–9.
- 39. Bonaccorsi G, Lorini C, Santomauro F, Guarducci S, Pellegrino E, Puggelli F, et al.
 Predictive factors associated with the acceptance of pandemic and seasonal influenza
 vaccination in health care workers and students in Tuscany, Central Italy. Hum Vaccin
 Immunother. 2013 Dec;9(12):2603–12.
- 40. Ribner BS, Hall C, Steinberg JP, Bornstein WA, Chakkalakal R, Emamifar A, et al. Use
 of a Mandatory Declination Form in a Program for Influenza Vaccination of Healthcare
 Workers. Infect Control Hosp Epidemiol. 2008 Apr;29(4):302–8.
- 590 41. Talbot TR, Dellit TH, Hebden J, Sama D, Cuny J. Factors Associated with Increased
 591 Healthcare Worker Influenza Vaccination Rates: Results from a National Survey of
 592 University Hospitals and Medical Centers. Infect Control Hosp Epidemiol. 2010
 593 May;31(5):456–62.
- 594 42. Thoon KC CC. Survey of healthcare workers' attitudes, beliefs and willingness to
 595 receive the 2009 pandemic influenza A (H1N1) vaccine and the impact of educational
 596 campaigns PubMed. Ann Acad Med Singapore. 2010;1(39):(4):307.

5

- 43. Rakita RM, Hagar BA, Crome P, Lammert JK. Mandatory Influenza Vaccination of
 Healthcare Workers: A 5-Year Study. Infect Control Hosp Epidemiol. 2010
 Sep;31(9):881–8.
- 600 44. Chyderiotis S, Seringe E, Blanckaert K, Guet L, Kadi Z, Astagneau P. Influenza
 601 vaccination coverage in healthcare workers during the 2014-2015 season. Antimicrob
 602 Resist Infect Control. 2015;4(Suppl 1):P18.
- 45. Harbarth S, Siegrist C-A, Schira J-C, Wunderli W, Pittet D. Influenza Immunization:
 Improving Compliance of Healthcare Workers. Infect Control Hosp Epidemiol. 1998
 May;19(5):337–42.
- 606 46. Organization WH. WHO | SAGE working group dealing with vaccine hesitancy (March
 607 2012 to November 2014). WHO. 2015;
- 608 47. Bedford H, Attwell K, Danchin M, Marshall H, Corben P, Leask J. Vaccine hesitancy,
 609 refusal and access barriers: The need for clarity in terminology. Vaccine. 2018
 610 Oct;36(44):6556–8.
- 611 48. Peretti-Watel P, Larson HJ, Ward JK, Schulz WS, Verger P. Vaccine hesitancy:
 612 Clarifying a theoretical framework for an ambiguous notion. PLoS Curr. 2015
 613 Feb;7(OUTBREAKS).
- 614 49. Oduwole EO, Pienaar ED, Mahomed H, Wiysonge CS. Current tools available for
 615 investigating vaccine hesitancy: A scoping review protocol. BMJ Open. 2019;9(12).
- 616 50. Opel DJ, Mangione-Smith R, Taylor JA, Korfiatis C, Wiese C, Catz S, et al.
 617 Development of a survey to identify vaccine-hesitant parents: The parent attitudes about
 618 childhood vaccines survey. Hum Vaccin. 2011;7(4).
- 619 51. de Figueiredo A, Simas C, Karafillakis E, Paterson P, Larson HJ. Mapping global trends
 620 in vaccine confidence and investigating barriers to vaccine uptake: a large-scale
 621 retrospective temporal modelling study. Lancet [Internet]. 2020;396(10255):898–908.

622	Available from:	http://dx.doi.org	g/10.1016/S0140	-6736(20)31558-0

- 52. Larson HJ, Schulz WS, Tucker JD, Smith DMD. Measuring vaccine confidence:
 Introducing a global Vaccine Confidence Index. PLoS Curr. 2015;7(OUTBREAKS).
- 625 53. Gilkey MB, Magnus BE, Reiter PL, McRee AL, Dempsey AF, Brewer NT. The
- 626 Vaccination Confidence Scale: A brief measure of parents' vaccination beliefs. Vaccine
- 627 [Internet]. 2014;32(47):6259–65. Available from:
- 628 http://dx.doi.org/10.1016/j.vaccine.2014.09.007
- 54. Sarathchandra D, Navin MC, Largent MA, McCright AM. A survey instrument for
 measuring vaccine acceptance. Prev Med (Baltim) [Internet]. 2018;109(January):1–7.
- 631 Available from: https://doi.org/10.1016/j.ypmed.2018.01.006
- 632 55. Health Organization W, Office for Europe R. The Guide to Tailoring Immunization
 633 Programmes (TIP) Increasing coverage of infant and child vaccination in the WHO
 634 European Region. 2013.
- 635 56. Grimshaw JM, Eccles MP, Lavis JN, Hill SJ, Squires JE. Knowledge translation of
 636 research findings. Implement Sci. 2012 Aug;7(1):50.
- 57. Dizon JM, Grimmer K, Machingaidze S, McLaren P, Louw Q. Mapping South African
 allied health primary care clinical guideline activity: Establishing a stakeholder
 reference sample. Heal Res Policy Syst. 2016 Oct;14(1):77.
- 640 58. Patton MQ. Qualitative Research & Evaluation Methods. 2001 Sage Publications.
 641 Thousand Oaks, California. 2014.
- 642 59. UNAIDS. Good participatory practice guidelines for biomedical HIV prevention trials.
 643 Vaccine. 2007;68.
- 644 60. Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol.
 645 2006;3(2):77–101.
- 646 61. Simms LJ. Classical and Modern Methods of Psychological Scale Construction. Soc

647 Personal Psychol Compass. 2008 Jan;2(1):414–33.

- 648 62. Betsch C, Habersaat KB, Deshevoi S, Heinemeier D, Briko N, Kostenko N, et al. Sample
- study protocol for adapting and translating the 5C scale to assess the psychological
- antecedents of vaccination. BMJ Open [Internet]. 2020 [cited 2020 Oct 28];10:34869.
- 651 Available from: http://bmjopen.bmj.com/
- 652 63. Anthoine E. Sample size used to validate a scale: a review of publications on n... -
- 653 PubMed NCBI. Health Qual Life Outcomes [Internet]. 2014;1–10. Available from:
- 654 http://www.ncbi.nlm.nih.gov/pubmed/25492701
- 655 64. Africa. ND of HS. Demographic and Health Survey 2016. 2016.
- 656 65. Dhs M. Sénégal Enquête Démographique et de Santé à Indicateurs Multiples. 2011 Sep;
- 657 66 https://www.who.int/emergencies/diseases/novel-coronavirus-2019 (Accessed 22 May
- 658 2022)
- 659
- 660
- 661
- 662
- 663
- 664
- 665
- 666
- 667
- 668
- 669
- 670
- 671

672 Appendix

- 673 1. Original 5C scale
- 674 2. Questionnaire
- 675 3. Informed consent form